MC

Molecular Cancer

Molecular Cancer is an internationally recognized journal focused on how basic cancer research drives advances in cancer prevention, diagnostics, and treatment. It is ranked in the top 25% in the Oncology category of Journal Citation Reports and welcomes submissions of broad interest including target therapies, molecular and cellular biology, genomics, genetics and epigenetics, pathology, and tumor immunology.

Looking to publish in Molecular Cancer? Livewrite integrates seamlessly with Word to help you write, edit, and format faster.

Try Livewrite Now
Subject Oncology
Impact Factor 33.9
Quartile Q1
Open Access Type Open
eISSN 1476-4598
Invitation Only No
Cost Range APC: £3690.00 GBP / $5290.00 USD / €4390.00 EUR, plus VAT or local taxes where applicable.

Submission Instructions

Molecular Cancer accepts the following article types. Click on an article type to view submission instructions.

Research Articles

Cover Letter A cover letter is required. The cover letter must explain why the manuscript should be published, address any issues relating to journal policies, declare any potential competing interests, confirm all authors approved the submission, and confirm the manuscript has not been published or submitted elsewhere.
Abstract A structured abstract is required. Abstract must not exceed 250 words. Abstract must be structured with separate sections. Abstract must include the headings Background, Methods, Results, and Conclusions.
Manuscript Main text should be around 5,000 words including the abstract. Manuscript must include Background, Methods, Results, Discussion, Conclusions, and a Declarations section. Manuscript must include three to ten keywords, a Declarations section with the specified subheadings including 'Not applicable' where relevant, a list of abbreviations if abbreviations are used, and documentation of any Large Language Model use in the Methods or another suitable section.
References References are limited to a maximum of 50. References must follow Vancouver style. Only published articles, clinical trial registration records, and abstracts that are published, in press, or publicly available as preprints may be cited, unpublished abstracts/data/personal communications must be excluded from the reference list, journal abbreviations must follow Index Medicus/MEDLINE, and URLs must be numbered and included in the reference list with full details and access date.
Figures & Tables Research articles must include 4 to 6 figures, not including tables. Figure titles and legends must appear in the main manuscript while figure files are uploaded separately, and tables under one page may be placed in the manuscript whereas larger tables may be placed at the end of the document. Figures discussing tumor-bearing mice must show only isolated tumors, new submissions must not contain images of animals bearing tumors, tumors must be excised and pictured next to a ruler for size comparison, other animal model figures must show full-size images as needed, multi-panel figures must be submitted as single composite files, and tables must not be embedded as figures or spreadsheet files.
Reformat to Molecular Cancer using Livewrite Premium

Reviews

Cover Letter A cover letter is required. Cover letter must explain why the manuscript should be published, address any issues relating to journal policies, declare any potential competing interests, confirm all authors approved the submission, confirm the manuscript has not been published or submitted elsewhere, and name the special issue if applicable.
Abstract A structured abstract is required. Abstract must be 350 words or fewer. Abstract must be structured with Background, Main body, and short Conclusion sections. Abstract must include the headings Background, Main body, and short Conclusion.
Manuscript Manuscript must include Background, Main text, and Conclusions sections, with the main text allowed to use short informative subsections. Manuscript must include three to ten keywords and an Availability of data and materials statement, and declarations for competing interests, authors' contributions, acknowledgements, and funding are also required.
References References must follow Vancouver style. Only published or in-press articles, clinical trial registration records, abstracts, and public preprints may be cited; unpublished abstracts, unpublished data, and personal communications must not appear in the reference list, journal abbreviations must follow Index Medicus/MEDLINE, and URLs must be numbered and listed in full with site title, URL, and access date.
Figures & Tables Figure titles and legends must appear in the main manuscript rather than in the graphic files, tables shorter than one page may be placed within the manuscript, and longer tables may be placed at the end with their intended position cited in the text. Figures must be numbered in order and uploaded in that order, multipanel figures submitted as single composite files, tumor-bearing mice figures limited to isolated tumors, other animal model figures shown full-size as needed, and tables must be numbered sequentially and created as tables rather than embedded as figures or spreadsheet files.
Reformat to Molecular Cancer using Livewrite Premium

Recent Publications

Beyond Darwin: reactive heredity, burst-drift dynamics and eco‑evolutionary control of cancer

Laurine Lagache, Julien Salzet, Isabelle Fournier, Michel Salzet

10.1186/s12943-026-02683-w
View Publication

Increased mRNA translation delays tumour initiation and exposes a therapeutic vulnerability in lung cancer

Luis Pardo, Madeleine Moore, Ruhi Deshmukh, Ian Powley, Joseph A. Waldron, Bjorn Kruspig, Lynn McGarry, Lobsang Dolma, America V. Campos, Colin Wood, Holly Leslie, Mark Hughes, Emanuel Jeldes, June Munro, Louise Mitchell, Leah Officer-Jones, Rachel Baird, Hugo Coquelet, Nigel B. Jamieson, David Sumpton, Douglas Strathdee, John le Quesne, Martin Bushell, Daniel J. Murphy, Jim C. Norman

10.1186/s12943-026-02680-z
View Publication

JAK-STAT signaling pathway in cancer: from molecular mechanisms to clinical intervention

Xiaoqian Zhang, Penghui Li, Fuqiang Ma, Tuokai Wang, Qingfei Chu, Shihui Wei, Chen Xue, Ziming Wang, Juan Lu

10.1186/s12943-026-02692-9
View Publication

CTHRC1 drives megakaryocyte-mediated immunotherapy resistance in esophageal squamous cell carcinoma via the integrin αIIbβ3/Rap1 pathway and is targetable by mRNA vaccination

Yixin Liu, Jianfeng Zhou, Mengyuan Song, Jian Wang, Qixin Shang, Jiajia Du, Yanxin Li, Xiangzheng Chen, Jing Wang, Xuerui Liao, Longqi Chen, Weimin Li, Yong Yuan, Yushang Yang, Yangping Wu

10.1186/s12943-026-02670-1
View Publication

The Treg-cell death axis in lung cancer: implications for immune evasion and novel therapeutic strategies

Wenping Fan, Qi An, Xiaoya Wang, Dongdong Qin, Zhenyu Zhao, Xueming Dong, Lingzhi Wang, Andrea Li-Ann Wong, Dong-Hua Yang, Boon-Cher Goh, Jinrui Dong

10.1186/s12943-026-02688-5
View Publication

Frequently asked questions

How long does it take to publish?

Submission to first decision (median): 3 days; less than 7 days time-to-first-decision.

Reformat to Molecular Cancer using Livewrite Premium

Is a cover letter required?

A cover letter is required. It should explain why the manuscript should be published in Molecular Cancer, address any issues relating to journal policies, declare potential competing interests, confirm all authors approved submission, confirm the work has not been published or submitted elsewhere, and mention the special issue name if applicable. Authors may also suggest preferred or non-preferred reviewers in the cover letter.

Reformat to Molecular Cancer using Livewrite Premium

What are the publication costs?

An article processing charge applies for each accepted article. The current APC is £3690.00 GBP / $5290.00 USD / €4390.00 EUR, plus VAT or local taxes where applicable.

Reformat to Molecular Cancer using Livewrite Premium

Research Topics

Cancer-related molecular mechanisms research MicroRNA in disease regulation Circular RNAs in diseases Cancer Cells and Metastasis RNA modifications and cancer Cancer, Hypoxia, and Metabolism Epigenetics and DNA Methylation Cancer Immunotherapy and Biomarkers Ferroptosis and cancer prognosis Cancer-related Molecular Pathways Immune cells in cancer Extracellular vesicles in disease Cell death mechanisms and regulation Cancer Genomics and Diagnostics Immunotherapy and Immune Responses Cancer-related gene regulation Wnt/β-catenin signaling in development and cancer Cancer Mechanisms and Therapy RNA Research and Splicing PI3K/AKT/mTOR signaling in cancer Ubiquitin and proteasome pathways Microtubule and mitosis dynamics Cytokine Signaling Pathways and Interactions Immune Cell Function and Interaction CAR-T cell therapy research

Related Journals

ID
Infectious Diseases Of Poverty BioMed Central
BM
Bmc Medicine BioMed Central
CJ
Chinese Journal Of Cancer Research AME PUBLISHING COMPANY
HA
Health And Quality Of Life Outcomes BioMed Central
HR
Health Research Policy And Systems BioMed Central
SC
Stem Cell Research & Therapy BioMed Central